Hereditary Breast and Ovarian Cancer Syndrome Treatment Market by...

Hereditary Breast and Ovarian Cancer Syndrome Treatment Market by Size, Share, Forecast, & Trends

Posted 2024-04-10 06:16:50

"Company profiles of all the major Hereditary Breast and Ovarian Cancer Syndrome Treatment Market players and brands dominating the Hereditary Breast and Ovarian Cancer Syndrome Treatment s Market with movements like product launches, joint ventures, mergers and acquisitions which in turn influence sales value, imports, exports, revenue and CAGR have been quoted in the report. The competitive landscape section of the report provides clear insights into the market share analysis of key industry players. The Hereditary Breast and Ovarian Cancer Syndrome Treatment s Market industry is expected to witness higher growth during the forecast period due to increasing demand at the end-user level. The Hereditary Breast and Ovarian Cancer Syndrome Treatment s Market analysis report helps to know how patents, licensing agreements, and other legal restrictions affect the manufacture and sale of a company's products.

The team of experts, in coordination with project managers, provides clients on every strategic aspect including product development, key areas of development, application modeling, use of technology, acquisition strategies, exploring special growth opportunities and new markets. A detailed analysis of factors influencing investment is also provided which estimates upcoming opportunities for the business and develops strategies to increase return on investment (ROI). Hereditary Breast and Ovarian Cancer Syndrome Treatment Market research reports offer actionable market insights so as to build sustainable and profitable business strategies.

Data Bridge Market Research analyses a growth rate in the hereditary breast and ovarian cancer syndrome treatment market in the forecast period 2023-2030. The expected CAGR of hereditary breast and ovarian cancer syndrome treatment market is tend to be around 5.3% in the mentioned forecast period. The market was valued at USD 6.2 billion in 2022, and it would grow up to USD 9.37 billion by 2030.

Explore Further Details about This Research Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Report https://www.databridgemarketresearch.com/reports/global-hereditary-breast-and-ovarian-cancer-syndrome-treatment-market

Hereditary Breast And Ovarian Cancer Syndrome Treatment Market Scope and Segmentation

REPORT METRIC	DETAILS
Forecast Period	2023 to 2030
Base Year	2022
Historic Years	2021 (Customizable to 2015 - 2020)
Quantitative Units	Revenue in USD Billion, Volumes in Units, Pricing in USD
Segments Covered	Treatment (Hormonal Therapy, Chemoprevention, Genetic Counseling, Medication, Others), Diagnosis (Genetic Testing, Magnetic Resonance Imaging (MRI), Mammography, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
Countries Covered	U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered	F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Merck KGaA (Germany), LEO Pharma A/S (Denmark), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Fresenius Kabi AG (Germany), Amneal Pharmaceuticals LLC. (U.S.)
Market Opportunities	Rising Strategic Developments and Acquisitions

Market Definition

Hereditary breast and ovarian cancer syndrome (HBOC) is a type of genetic disorder that increases the risk of ovarian, breast, and other cancers. This syndrome requires wide genetic counselling. Chemoprevention is also a possibility that is used widely for treatment. It can be caused by a mutation that is inherited in families. In this disease, a mutation in only 1 copy of the gene has an increased risk of getting that disease.

Hereditary Breast And Ovarian Cancer Syndrome Treatment Market Dynamics

Drivers

Rising Cases of Hereditary breast and ovarian cancer syndrome

The increasing incidence of hereditary breast and ovarian cancer syndrome is projected to enhance the market's growth rate. As per the Indian Council of Medical Research (ICMR), India is expected to have 17.3 lakh new cancer cases by 2020, with more than 8.8 lakh people dying from the disease. Furthermore, breast cancer, which has the highest occurrence of all cancers in women, has grown more common among those under the age of 50 years. Inherited genetic alterations can cause breast or ovarian cancer.

Increased Demand of Newborn Screening

A consistent increase in demand for newborn screening has led to a rise in sales of DNA testing kits. Growing penetration of newborn screening globally is further helping in revenue growth. Several reforms in genetic testing recommendations have led to the inclusion of multigene panel testing for hereditary cancer into clinical practice. Furthermore, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for ovarian, breast and colorectal cancers provide information on some cancer risk factors and management. The Virginia Department of General Services Division of Integrated Laboratory Facilities screened around 7,867 newborns for more than 31 genetic and metabolic illnesses in November 2019. Thus, all these screening is boosting the growth of the market.

Opportunities

Rising Strategic Developments and Acquisitions

There are several strategies that are being developed to boost the demand of the market. One of the strategies is providing hereditary tests at a price lower than what is by competitors. For instance, Color Genomics began selling its product for USD 259, however products offered by Myriad cost about USD 4,000. The growing affordability of the tests is one of the major drivers of this segment. There have been acquisitions between market players that is helping in expanding the growth. For instance, Quest Diagnostics, which is a supplier of diagnostic information services, announced in January 2020, the all-cash equity acquisition of Blueprint Genetics. As its known that Blueprint Genetics focuses in gene variant interpretation using next-generation sequencing (NGS) and proprietary bioinformatics, with this deal, Quest and Blueprint Genetics will improve patient care and pharmaceutical R&D by growing access to important insights into genetic and rare disorders.

Key questions answered in the Hereditary Breast and Ovarian Cancer Syndrome Treatment Market are:

What is Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?
What was the Hereditary Breast and Ovarian Cancer Syndrome Treatment Market size in 2022?
What are the different segments of the Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?
What growth strategies are the players considering to increase their presence in Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?
What are the upcoming industry applications and trends for the Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?
What are the recent industry trends that can be implemented to generate additional revenue streams for the Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?
What major challenges could the Hereditary Breast and Ovarian Cancer Syndrome Treatment Market face in the future?
What segments are covered in the Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?
Who are the leading companies and what are their portfolios in Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?
What segments are covered in the Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?
Who are the key players in the Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?